Elanco Animal Health Inc - ELAN STOCK NEWS

Merck Animal Health, a division of Merck & Co., Inc., is set to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, expanding its aqua portfolio with innovative products and technology solutions. The acquisition includes aqua manufacturing facilities, a research facility, and a portfolio of medicines, vaccines, and supplements for aquatic species. The deal is expected to be completed by mid-year 2024, subject to regulatory approvals and customary closing conditions.

Elanco Animal Health Incorporated (NYSE: ELAN) announced the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, reinforcing its focus on pet health and livestock sustainability. The transaction will enable Elanco to accelerate debt paydown by $1.05B to $1.1B, with net debt to adjusted EBITDA expected in the high-3x to low-4x range by the end of 2025. The aqua business generated an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA in 2023.

Elanco Animal Health Incorporated (NYSE: ELAN) has launched a multi-year campaign to save 1 million puppies from deadly canine parvovirus. The 'Defend Puppies. Defeat Parvo.' mission aims to conquer a virus with a 91% mortality rate, affecting an estimated 900 dogs daily in the U.S. Elanco seeks to increase education and awareness to protect puppies from this highly contagious disease.

The 2024 Feather in Her Cap awards ceremony honored 11 women for their outstanding career achievements in Animal Health, including Andrea J. Gonzales, Ph.D., of Zoetis, Inc. (NYSE: ZTS), and Katharina Bohnenblust, Ph.D., of Elanco Animal Health (NYSE: ELAN). Dr. Gonzales, Vice President of Global Companion Animal Therapeutics at Zoetis, was recognized for her leadership and contributions to the industry, while Dr. Bohnenblust received the 2024 High Flyer award for her accomplishments in pharmaceutical development. The awards aim to inspire the next generation of industry leaders and recognize women's achievements in Animal Health. Dr. Gonzales' passion for building an innovative R&D pipeline of animal health therapeutics and her commitment to mentoring women in the industry were highlighted, and she chose Cheff Therapeutic Riding Center in Kalamazoo, Michigan, as the recipient of a $5,000 charitable donation. Dr. Bohnenblust, who serves as a mentor for young female scientists, developed the new Elanco JAK-inhibitor formulation and manufacturing process. The Feather in Her Cap Association will reopen the nomination process in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.

Elanco Animal Health Incorporated (NYSE: ELAN) announced Lawrence E. Kurzius as the next Chairman of the Board, effective at the conclusion of the Company's 2024 Annual Meeting of Shareholders. The Board plans to rotate committee leadership and seek shareholder approval to modify the voting standard for uncontested director elections.

Elanco Animal Health Incorporated (NYSE: ELAN) to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Alveolus Bio (ALVB) announced a strategic scientific collaboration with BiomEdit, an animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals. The collaboration aims to study BiomEdit's proprietary consortium of commensal strains with anti-inflammatory and immune-modulating properties, as well as to explore the application of Alveolus Bio's resMIT platform for the development of respiratory therapeutics in companion animals.

Elanco Animal Health Incorporated (ELAN) to attend Evercore ISI 6th Annual HealthCONx Conference on November 28-29, 2023

Ziff Davis, Inc. (NASDAQ: ZD) appoints Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald, a highly accomplished executive with extensive experience in media, technology, and advertising, will bring valuable business leadership to Ziff Davis. He currently serves as CEO of GroupM North America and will leave the role at year end. With a career spanning over three decades, McDonald has held executive level leadership roles at prominent companies such as Warner Media's Xandr, Pubmatic, Time Inc., the Aquantive division of Microsoft, and CNET Networks. He also serves on the board of Elanco (NYSE: ELAN) and is a founding member of the Black Executive CMO Alliance. Kirk McDonald is widely respected in the industry and known for his leadership and innovation in the media and advertising ecosystem.